Aicuris reported Phase 3 success for pritelivir in immunocompromised patients with refractory HSV infections, meeting endpoints versus standard‑of‑care and setting up plans for a U.S. regulatory submission in 2026. The oral helicase‑primase inhibitor produced superior lesion healing in a patient population with high unmet need. The readout positions pritelivir as the first late‑stage oral option for difficult HSV cases and could reshape antiviral treatment options for immunosuppressed patients. Aicuris plans to advance regulatory filings and scale manufacturing in anticipation of potential approval. If approved, pritelivir would broaden the antiviral toolbox beyond nucleoside analogues and offer clinicians an oral alternative with a distinct mechanism, carrying commercial upside given the limited evolution in HSV therapeutics in recent decades.